Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials

By sjmartinez • February 11, 2023

Langley RG, Sofen H, Dei-Cas I, Reich K, Sigurgeirsson B, Warren RB, Paul C, Szepietowski JC, Tsai TF, Hampele I, You R, Charef P, Papavassilis C. Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials. Br J Dermatol. 2023 Feb 10;188(2):198-207. doi: 10.1093/bjd/ljac040. PMID: 36763857.

Tags: Dermatology, Publications

Laboratory monitoring in patients with moderate to severe plaque psoriasis

Fenkel JM, Osborne JA, Armstrong AW, Strober B, Stein Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis.[...]

Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX

Podolsky AS, Singal A, Goh C, Lipner SR. Alopecia areata is associated with adverse pregnancy outcomes in a retrospective cohort study using TriNetX. J Am[...]

Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials

Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, Bernstein JA, Kern JS, Ehst BD, Magnolo N, Herranz-Pinto P, Stein Gold L,[...]